论文部分内容阅读
目的研究血清及尿中高尔基体蛋白73(GP73)水平在前列腺癌诊断和治疗中的价值。方法选取前列腺癌患者100例(A组),前列腺增生患者(B组)和健康体检者(C组)各50例,比较三组血清GP73、总前列腺特异抗原(TPSA)、游离前列腺特异抗原(FPSA)和尿GP73的水平。结果 A组血清GP73、TPSA和FPSA水平高于C组,B组血清TPSA和FPSA水平高于C组(P<0.05);肝功能异常者血清GP73水平高于肝功能正常者(P<0.05);治疗后血清TPSA和FPSA水平低于治疗前(P<0.05),但血清和尿GP73水平在治疗前后无统计学差异(P>0.05)。结论血清和尿GP73检测在前列腺癌诊断和治疗中的价值不明显。
Objective To study the serum and urinary levels of Golgi apparatus protein 73 (GP73) in the diagnosis and treatment of prostate cancer. Methods A total of 50 prostate cancer patients (A group), benign prostatic hyperplasia (B group) and healthy volunteers (C group) were enrolled in this study. Serum GP73, total prostate specific antigen (TPSA), free prostate specific antigen FPSA) and urinary GP73 levels. Results The serum levels of GP73, TPSA and FPSA in group A were higher than those in group C, while the levels of TPSA and FPSA in group B were higher than those in group C (P <0.05). The level of GP73 in patients with abnormal liver function was higher than that in patients with normal liver function (P <0.05) The level of serum TPSA and FPSA after treatment was lower than that before treatment (P <0.05), but there was no significant difference in serum and urinary GP73 levels before and after treatment (P> 0.05). Conclusion Serum and urinary GP73 levels are not significant in the diagnosis and treatment of prostate cancer.